Event > Conference >
Drug Discovery 2024
Europe’s largest conference for the drug discovery community returns to London, with scientific tracks covering not only therapeutic themes such as mechanisms of ageing and cell & gene therapy, but also more practical aspects of drug discovery encompassing advances in assay design, applications in high content imaging, target identification and disease modelling.
Head to our poster #69
Our dedicated team of creative problem solvers will be available to answer questions and share over a decade of organ-on-a-chip (OOC) expertise with you!
We look forward to meeting you at Drug Discovery 2024 to discuss how our PhysioMimix® range of products and services can help to improve the predictivity of your toxicology workflows and address your current workflow limitations – such as modeling the immune system in vitro and testing the safety of new modality drugs with human-specific modes of action.
Get familiar with our human-relevant single- and multi-organ in vitro models and learn more about their proven track record for delivering clinically translatable results, plus meet the newest product in our PhysioMimix OOC range of microphysiological systems – the PhysioMimix Single-organ HT System and associated Multi-chip Liver-48 plate.
Poster Session
Defining validation criteria for a primary jejunum and primary hepatocyte dual-organ MPS: a promising tool for more predictive studies of human drug ADME and oral bioavailability
Poster board: 69
Date/time:
- Weds 2 Oct, 17:00 – 17:30
- Thurs 3 Oct, 13:00 – 13:30
Presenters: Dr. Marco Ortiz, CN Bio
Our Team at Drug Discovery
Adrian
A seasoned business developer with extensive commercial experience in the life science sector, Adrian Rea joined CN Bio as the European Director of Sales in June 2022. He brings valuable experience in the 3D cell culture market from his most recent role at InSphero, where he was responsible for developing business opportunities in European and Asian markets. He was previously Sales Director at Enzo Life Sciences, where he managed the restructuring of the global distributor sales channels and expanding the European sales operations. Adrian graduated from the University of Glasgow and received his PhD in pharmacology from Glasgow Caledonian University.
Marco
Marco Ortiz has experience in developing cell types as commercial products and clinical therapeutics. In his most recent role, he performed preclinical experiments of iPSCs derived hepatocytes for acute liver diseases as a potential indication. Marco Ortiz completed a bachelors in genomic sciences working at the University of Wisconsin-Madison and completed a UCL Wellcome Trust PhD programme at the Francis Crick Institute.